Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chi Leung Chiang"'
Autor:
Kazi Anisha Islam, Larry Ka-Yue Chow, Ngar Woon Kam, Ying Wang, Chi Leung Chiang, Horace Cheuk-Wai Choi, Yun-Fei Xia, Anne Wing-Mui Lee, Wai Tong Ng, Wei Dai
Publikováno v:
Cancers, Vol 14, Iss 9, p 2122 (2022)
This systematic review aims to identify prognostic molecular biomarkers which demonstrate strong evidence and a low risk of bias in predicting the survival of nasopharyngeal carcinoma (NPC) patients. The literature was searched for on PubMed to ident
Externí odkaz:
https://doaj.org/article/9a27abb4092b41bab22b7773135746c0
Publikováno v:
Cancers
Volume 15
Issue 4
Pages: 1105
Volume 15
Issue 4
Pages: 1105
This study aims to investigate the association of pre-treatment multi-phasic MR-based radiomics and dosimetric features with treatment response to a novel sequential trans-arterial chemoembolization (TACE) plus stereotactic body radiotherapy (SBRT) p
Autor:
Kwok-Hung Au, Macy Tong, Yuk Tung, Cheuk-Wai Horace Choi, Wai Tong Ng, Kai-Cheong Roger Ngan, Chung-Hang James Chow, Chun-Yin Edwin Wong, Ka-On Lam, Ka-Wai Alice Cheung, Wing-Mui Anne Lee, Pui-Lam Yip, Chi-Leung Chiang, Shing-Fung Lee, K.M. Cheung, Ho-Fun Lee, Ming-Chun Darren Poon, Wing-Yu Jessica Lai, Po-Chung Sunny Chan
Publikováno v:
Cancers, Vol 13, Iss 4286, p 4286 (2021)
Cancers
Volume 13
Issue 17
Cancers
Volume 13
Issue 17
A nomogram was recently published by Sun et al. to predict overall survival (OS) and the additional benefit of concurrent chemoradiation (CCRT) vs. radiotherapy (RT) alone, in stage II NPC treated with conventional RT. We aimed to assess the predicto
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 931, p 931 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 931, p 931 (2021)
Simple Summary There is a growing body of literature demonstrating high cancer drug costs relative to the benefits provided to patients treated on a large scale. We examined the cost-effectiveness of atezolizumab–bevacizumab for the first-line trea
Autor:
Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam, Chi-Leung Chiang, Chun-Yin Edwin Wong, Ming-Chun Darren Poon, Macy Tong, Kwok-Hung Au, Wai-Tong Ng, Kai-Cheong Roger Ngan, Wing-Mui Anne Lee, Yuk Stewart Tung
Publikováno v:
Cancers, Vol 13, Iss 17, p 4286 (2021)
A nomogram was recently published by Sun et al. to predict overall survival (OS) and the additional benefit of concurrent chemoradiation (CCRT) vs. radiotherapy (RT) alone, in stage II NPC treated with conventional RT. We aimed to assess the predicto
Externí odkaz:
https://doaj.org/article/0bfee1eecd8b480c88627a67e8a34cf6
Publikováno v:
Cancers, Vol 13, Iss 5, p 931 (2021)
Background: The IMbrave 150 trial revealed that atezolizumab plus bevacizumab (atezo–bev) improves survival in patients with unresectable hepatocellular carcinoma (HCC) (1 year survival rate: 67.2% vs. 54.6%). We assessed the cost-effectiveness of
Externí odkaz:
https://doaj.org/article/79b3b096048e4899a6c77ddd8042838a